Eli Lilly has delivered a robust financial performance in its latest quarter, significantly exceeding market expectations as global demand for its flagship GLP-1 medications, Mounjaro and Zepbound, continues to accelerate. The pharmaceutical leader reported revenue of $19.80 billion, marking a substantial 56% increase compared to the same period last year. This momentum has led the […]